Page last updated: 2024-12-06

alo 2145

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

apraclonidine hydrochloride : The hydrochloride salt of apraclonidine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID51763
CHEMBL ID1200379
CHEBI ID2789
SCHEMBL ID41138
MeSH IDM0067405

Synonyms (93)

Synonym
AC-12705
smr000058965
MLS000028829
p-aminoclonidine hydrochloride
aplonidine hydrochloride
iopidine
apraclonidine hydrochloride
alo-2145
EU-0100033
p-aminoclonidine hydrochloride, solid
2-((4-amino-2,6-dichlorophenyl)imino)imidazolidine monohydrochloride
1,4-benzenediamine, 2,6-dichloro-n(sup 1)-2-imidazolidinylidene-, monohydrochloride
2-(4-amino-2,6-dichlorophenylimino)imidazolidine hydrochloride
3,5-dichloro-4-(2-imidazolidinylidenimino)aniline hydrochloride
1,4-benzenediamine, 2,6-dichloro-n(sup 1)-(4,5-dihydro-1h-imidazol-2-yl)-, monohydrochloride
2,6-dichloro-n(sup 1)-(4,5-dihydro-1h-imidazol-2-yl)-1,4-benzenediamine monohydrochloride
nc 14 hydrochloride
2,6-dichloro-n(sup 1)-(2-imidazolidinylidene)-1,4-benzenediamine hydrochloride
apraclonidine hydrochloride [usan]
73218-79-8
apraclonidine hydrochloride (jan/usp)
D01008
NCGC00093552-01
A 0779
apraclonidine hcl
CHEBI:2789 ,
2,6-dichloro-n(1)-(4,5-dihydro-1h-imidazol-2-yl)-1,4-benzenediamine monohydrochloride
2,6-dichloro-n(1)-(2-imidazolidinylidene)-1,4-benzenediamine hydrochloride
al02145
CHEMBL1200379
al-02145
2,6-bis(chloranyl)-n1-(4,5-dihydro-1h-imidazol-2-yl)benzene-1,4-diamine hydrochloride
A837749
2,6-dichloro-n1-(4,5-dihydro-1h-imidazol-2-yl)benzene-1,4-diamine hydrochloride
apraclonidine hydrochloride [usan:usp]
unii-d2vw67n38h
d2vw67n38h ,
dtxcid4025749
dtxsid6045749 ,
tox21_111207
cas-73218-79-8
2-(4-amino-2,6-dichloroanilino)-2-imidazoline hydrochloride
al 02145
FT-0602878
LP00033
2-((4-amino-2,6-dichlorophenyl)imino) imidazolidine monohydrochloride
apraclonidine hydrochloride [mart.]
apraclonidine hydrochloride [usp impurity]
apraclonidine hydrochloride [usp monograph]
apraclonidine hydrochloride [mi]
apraclonidine hydrochloride [orange book]
apraclonidine hydrochloride [who-dd]
apraclonidine hydrochloride [jan]
apraclonidine hydrochloride [usp-rs]
S6583
CCG-221337
AKOS022175501
MLS006010230
SCHEMBL41138
OTQYGBJVDRBCHC-UHFFFAOYSA-N
2-[(2,6-dichloro-4-aminophenyl)imino]imidazolidine hydrochloride
tox21_500033
NCGC00260718-01
apraclonidine hydrochloride
AKOS025401362
mfcd00135922
sr-01000075247
SR-01000075247-1
DS-7631
2,6-dichloro-n1-(4,5-dihydro-1h-imidazol-
2-yl)benzene-1,4-diamine hydrochloride
Q27105817
apraclonidine (hydrochloride)
HY-12720A
alo 2145; aplonidine hydrochloride; apraclonidine hydrochloride; iopidine; p-aminoclonidine monohydrochloride
2,6-dichloro-1-n-(4,5-dihydro-1h-imidazol-2-yl)benzene-1,4-diamine;hydrochloride
CS-0031120
C76333
A937077
2-(4-amino-2,6-dichlorophenylimino)imidazolidinehydrochloride
73218-79-8 (apraclonidine hcl)
apraclonidine hydrochloride 100 microg/ml in acetonitrile:methanol
BA164186
apraclonidine hydrochloride ophthalmic solution
apraclonidine ophthalmic
apraclonidine hydrochloride (usan:usp)
iopidine 1%
apraclonidine hydrochloride (usp monograph)
1,4-benzenediamine, 2,6-dichloro-n(sup 1)-(4,5-dihydro-1h-imidazol-2-yl), monohydrochloride
apraclonidine hydrochloride (usp impurity)
2-((4-amino-2,6-dichlorophenyl)imino)-imidazolidine monohydrochloride
apraclonidine hydrochloride (usp-rs)
apraclonidine hydrochloride (mart.)

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
alpha-adrenergic agonistAn agent that selectively binds to and activates alpha-adrenergic receptors.
antiglaucoma drugAny drug which can be used to prevent or alleviate glaucoma, a disease in which the optic nerve is damaged, resulting in progressive, irreversible loss of vision. It is often, though not always, associated with increased pressure of the fluid in the eye.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
hydrochlorideA salt formally resulting from the reaction of hydrochloric acid with an organic base.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
endonuclease IVEscherichia coliPotency10.00000.707912.432431.6228AID1708
thioredoxin reductaseRattus norvegicus (Norway rat)Potency33.58750.100020.879379.4328AID588453
GLS proteinHomo sapiens (human)Potency28.18380.35487.935539.8107AID624170
glucocerebrosidaseHomo sapiens (human)Potency0.03550.01268.156944.6684AID2101
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency50.11870.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency79.43280.540617.639296.1227AID2364; AID2528
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency0.70790.01789.637444.6684AID588834
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's3 (50.00)24.3611
2020's2 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.13 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]